PRINCETON, N.J., Dec. 22 /PRNewswire/ -- Medarex and its licensees have advanced 16 fully human antibodies derived from Medarex's UltiMAb Human Antibody Development System(R) either into human clinical trials or regulatory applications have been submitted to begin such trials.
Genmab A/S recently announced the filing of an Investigational New Drug application and a Clinical Trial Application in England for HuMax-CD20 for the treatment of non-Hodgkin's lymphoma. HuMax-CD20 is the sixteenth UltiMAb-derived antibody to begin the clinical development process.
Five antibody therapeutics are under development by Medarex for a variety of diseases, including melanoma, prostate cancer, breast cancer, HIV, Hodgkin's lymphoma and anaplastic large cell lymphoma as well as autoimmune diseases. Medarex licensees, including Genmab A/S, Centocor/J&J, and Novartis among others, are developing fully human antibodies for diseases such as cancer, lymphoma, rheumatoid arthritis, psoriasis and other autoimmune diseases. |
